Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00891384 | Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 194 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY |
| 21 |
| Jan 19, 2018 |
| clinicaltrials |
| NCT03402295 | Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation(GBRAM003r) | completed | Phase 3 | 311 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 0 | Jan 18, 2018 | clinicaltrials |
| NCT00004874 | Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | terminated | Phase 3 | 31 | University of NebraskaOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00562965 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 14 | Jan 9, 2018 | clinicaltrials |
| NCT03391726 | CART-19 Cells for R/R B-cell Lymphoma(CCFRRBL) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | unknown | Phase 3 | 870 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 5 | Dec 19, 2017 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT00083915 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | completed | Phase 3 | 97 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | terminated | Phase 3 | 20 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00657553 | Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77) | terminated | Phase 3 | 10 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00310167 | Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma(FoRT) | completed | Phase 3 | 614 | University College, LondonOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | unknown | Phase 3 | 648 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01701232 | Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma | completed | Phase 3 | 174 | BiocadINDUSTRY | 5 | Nov 6, 2017 | clinicaltrials |
| NCT00056160 | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 353 | CelgeneINDUSTRY | 2 | Oct 19, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT01457040 | Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT03229616 | BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 572 | Hoffmann-La RocheINDUSTRY | 27 | Oct 11, 2017 | clinicaltrials |
| NCT01916252 | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old(GEM2012MENOS65) | completed | Phase 3 | 460 | PETHEMA FoundationOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02248428 | Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma(CTd) | unknown | Phase 3 | 130 | Jinling Hospital, ChinaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00516503 | Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer | completed | Phase 3 | 208 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00929695 | Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease | completed | Phase 3 | 164 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01144364 | A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 234 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01500083 | Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia(BENDACT) | completed | Phase 3 | 90 | Lundbeck Canada Inc.INDUSTRY | 1 | Aug 14, 2017 | clinicaltrials |
| NCT00355199 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | completed | Phase 3 | 246 | Gruppo Italiano Terapie Innovative nei LinfomiOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00090051 | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | completed | Phase 3 | 552 | Hoffmann-La RocheINDUSTRY | 17 | Aug 1, 2017 | clinicaltrials |
| NCT03016000 | Thalidomide Maintenance Treatment in DLBCL | unknown | Phase 3 | 226 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03018626 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | unknown | Phase 3 | 402 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00801281 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.(PLRG4) | completed | Phase 3 | 250 | Polish Lymphoma Research GroupNETWORK | 1 | Jul 17, 2017 | clinicaltrials |
| NCT02871869 | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 2 / Phase 3 | 316 | Xinjiang Medical UniversityOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00719472 | A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)(RATE) | completed | Phase 3 | 451 | Genentech, Inc.INDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT03151044 | R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL | unknown | Phase 3 | 408 | FENG Ji-fengOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT00324324 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | terminated | Phase 3 | 240 | OHSU Knight Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00554164 | Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas(PETAL) | completed | Phase 3 | 1,073 | University Hospital, EssenOTHER | 1 | May 5, 2017 | clinicaltrials |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma(FOCUS) | completed | Phase 3 | 315 | AmgenINDUSTRY | 19 | May 2, 2017 | clinicaltrials |
| NCT03123718 | High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL | unknown | Phase 3 | 205 | Chonnam National University HospitalOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00816049 | ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy(ALL2008con) | completed | Phase 3 | 775 | Rigshospitalet, DenmarkOTHER | 5 | Apr 21, 2017 | clinicaltrials |
| NCT00819351 | ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase | completed | Phase 3 | 650 | Rigshospitalet, DenmarkOTHER | 5 | Apr 21, 2017 | clinicaltrials |
| NCT00025259 | Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | completed | Phase 3 | 1,734 | Children's Oncology GroupNETWORK | 7 | Apr 12, 2017 | clinicaltrials |
| NCT00097981 | A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 225 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00732641 | Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | completed | Phase 3 | 244 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2017 | clinicaltrials |
| NCT00140582 | Primary Rituximab and Maintenance | completed | Phase 3 | 1,217 | Lymphoma Study AssociationOTHER | 12 | Mar 13, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 19, 2018source: clinicaltrials